Appetite and food intake results from phase I studies of anamorelin

What Was Tested

This randomized controlled trial paper looks at Anamorelin (non-peptide).

Loss of appetite and body weight are potentially devastating, highly prevalent cancer complications.

The ghrelin receptor is a mediator of appetite and metabolism, and anamorelin is a novel, orally administered ghrelin receptor agonist.

Who Took Part

PubMed indexes the participants as young adults and adults, both men and women.

Both trials were phase I, randomized, double-blind, placebo-controlled, partly/wholly crossover studies of healthy young adults.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Because people in this Anamorelin (non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Anamorelin (non-peptide) study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Anamorelin (non-peptide) could be set against what happens without it.

In the crossover set-up each of the participants took both Anamorelin (non-peptide) and the comparison in turn, acting as their own control.

What Was Measured

Effects on appetite and food intake may influence body-weight gain but can be difficult to measure in multi-site studies.

PubMed files the paper under topics including Appetite, Eating, Hydrazines and Oligopeptides.

The authors tagged it with the keywords Anamorelin, Cancer cachexia, Food intake and Phase I studies.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Anamorelin (non-peptide).

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (Journal of cachexia, sarcopenia and muscle), a journal based in Germany.

More context: the Anamorelin (non-peptide) compound page, all human trials.